pemigatinib tablets

Pemigatinib, a potent and selective oral inhibitor of FGFR isoforms 1/2/3 [3], has been approved by the National Medical Products Administration in China for the treatment of adult patients with advanced, metastatic or unresectable cholangiocarcinoma who have received at least one prior systemic therapy and have been tested positive for FGFR2 fusions or rearrangements. [2]
Daburtan® was jointly developed by Incyte and Innovent Biologics, which is responsible for commercialization in mainland China, Hong Kong, Macau and Taiwan. [3] Daburtan is the first selective FGFR receptor tyrosine kinase inhibitor approved in China. [1]
Daburtan (pemigatinib) has been approved by the National Medical Products Administration for the treatment of adult patients with advanced, metastatic or unresectable cholangiocarcinoma who have received at least one prior systemic therapy and have been tested positive for fibroblast growth factor receptor 2 (“FGFR2”) fusions or rearrangements [2]. [1]